Bisoctrizole/titanium dioxide

Drug Profile

Bisoctrizole/titanium dioxide

Alternative Names: Bisoctrizole/titanium dioxide pigmentary/titanium dioxide microfine; RV3131A-MV1166; Titanium dioxide/bisoctrizole; V-0096-CR

Latest Information Update: 22 May 2014

Price : $50

At a glance

  • Originator Orfagen
  • Class Peroxides; Phenols; Sunscreens; Triazoles
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Skin disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Skin disorders

Most Recent Events

  • 22 May 2014 Discontinued - Phase-II for Skin disorders in United Kingdom (Topical)
  • 22 May 2014 Discontinued - Phase-II for Skin disorders in USA (Topical)
  • 23 Jul 2013 Bisoctrizole/titanium dioxide withdrawn from Community Register of Orphan Medicinal Products in EU on request of Orfagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top